Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
about
Emerging therapeutic agents for lung cancerAdvances in Cancer Immunotherapy in Solid TumorsImmunological effect of local ablation combined with immunotherapy on solid malignancies.Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRCurrent state of immunotherapy for non-small cell lung cancer.Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies.Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancerThe potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodesThe Promise and the Hype of 'Personalised Medicine'.Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.New insights into the role of EMT in tumor immune escape.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.Checkpoint Blockade in Lung Cancer and Mesothelioma.Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.What does PD-L1 positive or negative mean?Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.Companion diagnostics-a tool to improve pharmacotherapy.Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine.Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrom targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextPembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.The significance of programmed cell death ligand 1 expression in resected lung adenocarcinomaUpdate on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trialSOX2 immunity and tissue resident memory in children and young adults with glioma.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
P2860
Q28070165-B3D5DF0B-4BF5-4DA2-B3B2-47330A7D002DQ28080113-F92386CB-44A6-494B-9AD1-18AAAFFBD695Q30354580-C01AE5F5-631D-4D2F-86C7-3E853226750FQ33618558-809F14FA-7124-4546-8929-8FCFC665DFB9Q33645595-7E3E0278-AF3A-4491-90C9-8B591C66BEDAQ33645607-C249FC0E-35AC-4AC0-8D78-177287414A7CQ33645624-2AF8EB71-EC0A-47A2-B5E8-6339267220A5Q33656860-C1C91CEC-FCA2-463F-8F3A-F6A85E074864Q33704061-3751447F-5DB2-4BF9-890B-A8263AEC8DC3Q33718731-4CF2394C-7795-4C65-B433-40993D94F3BAQ33738293-4E1E1C15-6EC4-43E3-8164-84E97B54A2C6Q33763622-D6E4F452-D78C-4875-B48F-661BD895D624Q33819820-3FD2394C-F910-4192-A84C-0DDC87ABE5BCQ33850467-2BB32BF8-3549-4D8D-88AF-E237773889EAQ33869781-EB6999FA-334C-40DB-98DE-9594D05CAC51Q33876861-7B821305-56A6-4785-9089-5AC166BB0E56Q33890538-65BC92A4-14BB-4B6B-A4C8-4669BDD36184Q36295004-C0453357-3910-491E-8A20-C05A1FAF794EQ36305457-6472CEAA-E9D9-4BDA-B050-71A0E3388C22Q36352476-95872D7B-C990-4799-B350-8E58533DE168Q36382143-5736E5F3-2A28-4EA1-800D-4D5323B6B9A6Q36400381-9270DCD0-52CC-40DF-A2A5-5842B7B43E26Q36409040-C384FDAB-7D85-4BFE-AD32-31A7C9C4CCD1Q37500381-C9CC1567-74EF-4D77-BB0C-1E09A4FD9FE8Q37573430-2E59CCF7-24FE-4A8B-A182-27C34641CE72Q37583823-3B91112E-6380-4CC5-9CE2-8815D77932AEQ37592628-8E83B21B-BF7D-4829-B1C9-799D62397AF9Q37598057-66BDB287-022A-4785-A91F-CF40BEFE8108Q37629874-C6A4A68C-3882-4FD8-BCFD-DC1AB005BF03Q37642460-D08D0D16-9607-4FB0-B33F-46D27C7365E7Q37669352-E94A69F0-3363-4DF2-9F84-56F4951992ADQ37688658-4F14E6C3-D0C6-4BF5-9855-66DD7C54C2CEQ37695065-6DF31297-99F8-4AE5-A2A9-51F7B1B58075Q37721218-9BEF16B4-5844-4A75-84F2-B795C035B759Q37725446-F2E5FC6D-D531-4149-A8E3-4628E7A6BC81Q37739214-1A92F6DF-E100-47E5-BE2E-870FF6A86AB8Q37741383-D4FFD518-0C2B-4395-91A9-3155BEC29459Q38372645-A3C1FAF8-F8EF-4495-A1AE-8F8C52DE5A72Q38373829-20263335-730A-42B3-9D99-68F26105B663Q38401891-7AF78B12-EACB-4D97-BD50-71B3250712A3
P2860
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
@en
type
label
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
@en
prefLabel
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
@en
P2093
P356
P1476
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
@en
P2093
Ali Tafreshi
Andrea Fülöp
Andrew G Robinson
Delvys Rodríguez-Abreu
Gregory M Lubiniecki
Julie R Brahmer
KEYNOTE-024 Investigators
Katsuyuki Hotta
Martin Reck
Mary O'Brien
P304
P356
10.1056/NEJMOA1606774
P407
P577
2016-10-08T00:00:00Z